TITLE

Luliconazole for the treatment of fungal infections: an evidence-based review

AUTHOR(S)
Khanna, Deepshikha; Bharti, Subhash
PUB. DATE
September 2014
SOURCE
Core Evidence;2014, Vol. 9, p113
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Preclinical studies have demonstrated excellent activity against dermatophytes. Further, in vitro/in vivo studies have also shown favorable activity against Candida albicans, Malassezia spp., and Aspergillus fumigatus. Luliconazole, although belonging to the azole group, has strong fungicidal activity against Trichophyton spp., similar to that of terbinafine. The strong clinical antifungal activity of luliconazole is possibly attributable to a combination of strong in vitro antifungal activity and favorable pharmacokinetic properties in the skin. Clinical trials have demonstrated its superiority over placebo in dermatophytosis, and its antifungal activity to be at par or even better than that of terbinafine. Application of luliconazole 1% cream once daily is effective even in short-term use (one week for tinea corporis/cruris and 2 weeks for tinea pedis). A Phase I/IIa study has shown excellent local tolerability and a lack of systemic side effects with use of topical luliconazole solution for onychomycosis. Further studies to evaluate its efficacy in onychomycosis are underway. Luliconazole 1% cream was approved in Japan in 2005 for the treatment of tinea infections. It has recently been approved by US Food and Drug Administration for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis. Topical luliconazole has a favorable safety profile, with only mild application site reactions reported occasionally.
ACCESSION #
98710495

 

Related Articles

  • Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Lieberman, Daniel Z.; Massey, Suena H. // Core Evidence;2009, Vol. 4 Issue 1, p67 

    Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of...

  • Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild // Core Evidence;2009, Vol. 4 Issue 1, p247 

    Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new...

  • Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Krulig, Eliana; Gordon, Kenneth B. // Core Evidence;2010, Vol. 5 Issue 1, p11 

    Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated...

  • Lasofoxifene: Evidence of its therapeutic value in osteoporosis. Gennari, Luigi; Merlotti, Daniela; De Paola, Vincenzo; Nuti, Ranuccio // Core Evidence;2009, Vol. 4 Issue 1, p113 

    Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affecting up to 40% postmenopausal women and 15% of men. Among the several...

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

  • Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Gaffo, Angelo L.; Saag, Kenneth G. // Core Evidence;2009, Vol. 4 Issue 1, p25 

    Introduction: Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group...

  • Effects of Expiratory Muscle Strength Training on Videofluoroscopic Measures of Swallowing: A Systematic Review. Mancopes, Renata; Smaoui, Sana; Steele, Catriona M. // American Journal of Speech-Language Pathology;Feb2020, Vol. 29 Issue 1, p335 

    Purpose: Expiratory muscle strength training (EMST) is increasingly utilized in dysphagia rehabilitation; however, little is known about the effects of this approach on swallowing function or physiology. We conducted a systematic review to appraise and synthesize evidence regarding the effects...

  • Complementary feeding and developmental milestones: a systematic review. English, Laural K; Obbagy, Julie E; Wong, Yat Ping; Butte, Nancy F; Dewey, Kathryn G; Fox, Mary Kay; Greer, Frank R; Krebs, Nancy F; Scanlon, Kelley S; Stoody, Eve E // American Journal of Clinical Nutrition;2019 Supplement, Vol. 109, p879S 

    Background Systematic reviews were conducted as part of the USDA and the US Department of Health and Human Services Pregnancy and Birth to 24 Months Project to examine the relation between complementary feeding and developmental milestones. Objectives The aim of this study was to describe...

  • Occupational Therapy for Adults with Overweight and Obesity: Mapping Interventions Involving Occupational Therapists. Nielsen, Svetlana Solgaard; Christensen, Jeanette Reffstrup // Occupational Therapy International;10/30/2018, p1 

    Background. Worldwide obesity rates are increasing. The effectiveness of occupational therapy in overweight and obese adults has not yet been clarified. Objectives. The scoping review aimed at examining the evidence on interventions involving occupational therapists in the treatment of adults...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics